Drug Type Small molecule drug |
Synonyms Concentrated Divitamins and Sodium, Concentrated Divitamins and Sodium Phoshate Syrup, Concentrated Divitamins and Sodium Phosp + [25] |
Target |
Action inhibitors |
Mechanism 30S subunit inhibitors(30S ribosomal subunit inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (12 Dec 1980), |
RegulationOrphan Drug (United States) |
Molecular FormulaC18H37N5O9 |
InChIKeyNLVFBUXFDBBNBW-PBSUHMDJSA-N |
CAS Registry32986-56-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00063 | Tobramycin |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Bronchiectasis | China | 11 Oct 2022 | |
Cystic Fibrosis | Japan | 28 Sep 2012 | |
Cystic Fibrosis | Japan | 28 Sep 2012 | |
Infectious Lung Disorder | European Union | 20 Jul 2011 | |
Infectious Lung Disorder | Iceland | 20 Jul 2011 | |
Infectious Lung Disorder | Liechtenstein | 20 Jul 2011 | |
Infectious Lung Disorder | Norway | 20 Jul 2011 | |
Pseudomonas Infections | United States | 22 Dec 1997 | |
Pseudomonas Infections | United States | 22 Dec 1997 | |
Acute Bronchitis | Japan | 01 Mar 1986 | |
Cystitis | Japan | 01 Mar 1986 | |
Hemorrhagic Septicemia | Japan | 01 Mar 1986 | |
Peritonitis | Japan | 01 Mar 1986 | |
Pneumonia | Japan | 01 Mar 1986 | |
Pyelonephritis | Japan | 01 Mar 1986 | |
Pyoderma | Japan | 01 Mar 1986 | |
Secondary infection | Japan | 01 Mar 1986 | |
Blepharitis | Japan | 07 Dec 1981 | |
Conjunctivitis | Japan | 07 Dec 1981 | |
Corneal Ulcer | Japan | 07 Dec 1981 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pseudomonas aeruginosa infection | Phase 3 | Estonia | 12 Aug 2009 | |
Pseudomonas aeruginosa infection | Phase 3 | Russia | 12 Aug 2009 | |
Cataract | Phase 3 | United States | 01 Feb 2009 | |
Eye Infections | Phase 3 | United States | 01 Jul 2005 | |
Postoperative Complications | Phase 3 | United States | 01 Jul 2005 | |
Non-cystic fibrosis bronchiectasis | Phase 2 | Belgium | 08 Feb 2017 | |
Non-cystic fibrosis bronchiectasis | Phase 2 | France | 08 Feb 2017 | |
Non-cystic fibrosis bronchiectasis | Phase 2 | Germany | 08 Feb 2017 | |
Non-cystic fibrosis bronchiectasis | Phase 2 | Italy | 08 Feb 2017 | |
Non-cystic fibrosis bronchiectasis | Phase 2 | Spain | 08 Feb 2017 |
Phase 3 | 11 | (Antibiotic) | lxinafidxj = ftwgqvibnf ylttfkoauq (mcnichhbyz, dhjmldpgiy - bchjfnktom) View more | - | 15 Jun 2023 | ||
Placebo: normal saline (Normal Saline) | lxinafidxj = chmkgsqivh ylttfkoauq (mcnichhbyz, ysgtzjkdgz - vwerdlxozb) View more | ||||||
Phase 4 | 16 | Aerosolized Placebo (Aerosolized Placebo) | wdayblbzww(bxnammzrqn) = pwbfbpxjzp wwfxndwntn (wiaanswuzo, gogbucyavf - undcjyidhr) View more | - | 22 May 2023 | ||
(Aerosolized Tobramycin or Vancomycin) | wdayblbzww(bxnammzrqn) = gqmhkkhjip wwfxndwntn (wiaanswuzo, zfwcpvvesv - chpelsfdwp) View more | ||||||
Phase 2/3 | Non-cystic fibrosis bronchiectasis Maintenance | 58 | nleoffbgeu(auypgxswka): RR = 0.74 (95% CI, 0.49 - 1.14), P-Value = 0.15 | - | 03 Dec 2022 | ||
Placebo | |||||||
Phase 4 | 51 | (Standard Colistin Arm) | ayuobjfnco(myibcqrdhf) = swpeskpsza ofvorxmjue (dsjmgnfuja, 9.5) View more | - | 06 Oct 2022 | ||
(Modified Colistin Arm) | ayuobjfnco(myibcqrdhf) = fevnplatjn ofvorxmjue (dsjmgnfuja, 3.0) View more | ||||||
Phase 1/2 | 19 | (Tobramycin Topical Antibiotic Nasal Saline Rinse) | chovuapkmb = isuhbmjanb ajjvhknbpz (xwcajencvo, tqiqjobozj - yebdhayjwl) View more | - | 20 Apr 2022 | ||
(Levofloxacin Topical Antibiotic Nasal Saline Rinse) | chovuapkmb = rljdbhrych ajjvhknbpz (xwcajencvo, owdsvfzpjw - lclsyewwzn) View more | ||||||
Phase 3 | 49 | vankoqsgya = dwikpxrjnm bazolqenql (szlahooqsa, rjnmtulfwq - lgnsmzxdjc) View more | - | 02 Jun 2021 | |||
Not Applicable | 200 | TIP (Cellular variant of primary FSGS) | exbwrtjgqx(uezfzuhuge) = qwhybwimro soldsjdxer (xmnwgpluuj ) | Positive | 29 May 2021 | ||
Phase 2 | Non-cystic fibrosis bronchiectasis Pseudomonas aeruginosa | 107 | yzsrqzqzax(prvdfpdkgz) = 37.4% ekpgntwnlg (mxhnmhvnax ) View more | - | 01 Jan 2021 | ||
Phase 1 | 10 | swqorhfonf(himwxalqhj) = vpfsxmmcvn vzmonakhqb (kdrlowvonl, jphtmwrizv - wszknztnno) View more | - | 04 Nov 2020 |